DENVER--(BUSINESS WIRE)--Accelr8 Technology Corporation (Amex: AXK) announced today that the company and its research collaborators have completed two studies that characterize technical advances for its BACcel™ rapid diagnostic system. The system is being developed to rapidly identify bacteria and their antibiotic resistance mechanisms. Targeted organisms include multi-drug resistant organisms or so-called “superbugs” such as MRSA, Pseudomonas, Acinetobacter, and Klebsiella.
